Caplin Point Laboratories Ltd-Fundamental and Technical analysis view

CEO: Sridhar Ganesan

Founded: 1990

Small Cap Company, market cap: 4067.69 (Cr)

Fundamental View:

The company is profit making, reserve and surpluses are in increasing order from the last 5 years. This is a very good sigh. The company is with zero promotor pledge, and working with low debt these are positive points. Quarterly results also sound good and expecting more improvement in the future.

Quarterly	JUN 2020	MAR 2020	DEC 2019	SEP 2019	JUN 2019
Sales	240	215	228	227	192
Other Income	6	19	10	6	4
Total Income	246	234	238	234	197
Total Expenditure	177	169	168	163	132
EBIT	69	65	69	70	64
Interest	0	0	0	0	0
Tax	14	16	10	13	14
Net Profit	54	48	58	57	50

Trending

Caplin point ltd is a pharmaceutical company. The Company’s product segments include Antibiotics, Non-steroidal anti-inflammatory drugs (NSAIDs), Ophthalmic, Pain Management, and Anti-ulcers this is useful for the treatment of COVID-19 patients. This is the main reason to increase in sales quarter by quarter. Nowadays the pharma sector is performing well as compared to other sectors so investing in pharma is worthy.

Technical Analysis:

Hammer found on the chart on daily basis. Price has given positive breakout on monthly and Weekly candles, this chart expecting positive movement in the short-term and medium-term. Buy above 545 and keep the stop loss on 509, for the first target 602 and second target 647 for short-term and medium-term.